Another look at pharma news to July 21

23 July 2017

The US Food and Drug Administration’s actions were behind some of the leading pharma and biotech news last week. This included marketing approval for Johnson & Johnson’s plaque psoriasis drug candidate Tremfya and Gilead Sciences latest hepatitis C drug Vosevi, as well as a setback for Amgen’s osteoporosis treatment Evenity. Added to this, was the welcome news that Novartis and Amgen’s migraine drug erenumab New Drug Application has been accepted by the agency.

Approval of Tremfya is huge win for shareholders

The FDA approval of Johnson & Johnson's Tremfya, a treatment for patients with plaque psoriasis means Novartis, Eli Lilly and Valeant Pharmaceuticals International could see some competition in this space. This is a good opportunity for investors to go long J&J stock, says blogger “Long Term Bio” writing on Seeking Alpha.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK